학술논문

Costello syndrome: Clinical phenotype, genotype, and management guidelines.
Document Type
article
Source
American journal of medical genetics. Part A. 179(9)
Subject
Face
Heart
Humans
Heart Defects
Congenital
Abnormalities
Multiple
Developmental Disabilities
Gene Expression Regulation
Genotype
Phenotype
Germ-Line Mutation
Disease Management
Proto-Oncogene Proteins p21(ras)
Guidelines as Topic
Costello Syndrome
Costello syndrome
HRAS mutation
RAS/MAPK
RASopathy
management guidelines
Genetics
Pediatric
Congenital Structural Anomalies
Health Services
Clinical Research
Management of diseases and conditions
7.3 Management and decision making
Good Health and Well Being
RAS
MAPK
Clinical Sciences
Language
Abstract
Costello syndrome (CS) is a RASopathy caused by activating germline mutations in HRAS. Due to ubiquitous HRAS gene expression, CS affects multiple organ systems and individuals are predisposed to cancer. Individuals with CS may have distinctive craniofacial features, cardiac anomalies, growth and developmental delays, as well as dermatological, orthopedic, ocular, and neurological issues; however, considerable overlap with other RASopathies exists. Medical evaluation requires an understanding of the multifaceted phenotype. Subspecialists may have limited experience in caring for these individuals because of the rarity of CS. Furthermore, the phenotypic presentation may vary with the underlying genotype. These guidelines were developed by an interdisciplinary team of experts in order to encourage timely health care practices and provide medical management guidelines for the primary and specialty care provider, as well as for the families and affected individuals across their lifespan. These guidelines are based on expert opinion and do not represent evidence-based guidelines due to the lack of data for this rare condition.